A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oraxol in Subjects With Advanced Malignancies
A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oraxol in Subjects With Advanced Malignancies
Sponsor: Atlantic Research Group
This PHASE1 trial investigates Solid Tumor and is currently completed. Atlantic Research Group leads this study, which shows 8 recorded versions since 2013 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Oct 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Oct 2021 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
▶ Show 3 earlier versions
-
May 2018 — Jun 2018 [monthly]
Completed PHASE1
-
Feb 2017 — May 2018 [monthly]
Completed PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1
First recorded
Oct 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Atlantic Research Group
- Kinex Pharmaceuticals Inc.
For direct contact, visit the study record on ClinicalTrials.gov .